Press Releases

Vancouver, British Columbia--(Newsfile Corp. - June 12, 2024) - Solution Financial Inc. (TSX: SFI) (the "Company") a leading provider of luxury and ultra luxury asset leasing in Canada, today announced its financial results for the second quarter ending April 30, 2024.

Earnings Highlights for the Quarter:

• Revenues were $2.3 million compared to $3.5 million in the comparative quarter.
• Net loss for the quarter was $29,046 compared to net income of $37,826 in the... (continue reading...)

LONDON--(BUSINESS WIRE)-- Regulatory News:

Pershing Square Holdings, Ltd. (LN: PSH) (LN:PSHD) (NA: PSH) today released its regular weekly Net Asset Value (“NAV”) and performance returns on its website, https://pershingsquareholdings.com/performance/net-asset-value-and-returns/. The NAV and returns were computed as of the close of business on Tuesday, 11 June 2024.

PSH NAV per share as of close of business on 11 June 2024 was 69.21 USD / 54.32 GBP and... (continue reading...)

LOS ANGELES, June 12, 2024 /PRNewswire/ -- Azazie, the Leading DTC Bridal Brand, is thrilled to announce the release of its definitive guide to destination wedding dresses and bridesmaid dresses for the 2024 summer brides. As the world becomes more connected and couples seek out unique venues to exchange vows, Azazie is at the forefront, offering an exquisite collection tailored to meet the dreams of every bride embarking on a destination wedding journey.

Wedding... (continue reading...)

TORONTO--(BUSINESS WIRE)-- DREAM RESIDENTIAL REAL ESTATE INVESTMENT TRUST (TSX:DRR.U and TSX:DRR.UN) (“Dream Residential REIT” or the “REIT”) announced that, at its annual meeting of unitholders (the “Meeting”) held today, all of the nominees for election as trustees of the REIT (the “Trustees”) referred to in its management information circular for the Meeting were elected. Votes cast on this matter were as follows:

Nominee

Votes For

% Votes... (continue reading...)

US patients aged 10 years and older can now benefit from FARXIGA for type-2 diabetes

Approval based on results from T2NOW, one of the largest pediatric type-2 diabetes Phase III trials to date

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older.1 The FDA approval was based on... (continue reading...)